Vizient Applauds FDA Approval of Biosimilar UDENYCA

Release Date:
Monday, November 5, 2018 1:00 pm EST

Terms:

Dateline City:
IRVING, Texas

IRVING, Texas--(BUSINESS WIRE)--Vizient [14] announces its support for the approval of UDENYCA™ (pegfilgrastim-cbqv), the second pegfilgrastim biosimilar approved by the Food and Drug Administration (FDA) and the first to be authorized by both the U.S. and the European Commission for patients with cancer receiving myelosuppressive chemotherapy. UDENYCA is the first drug from Coherus BioSciences, Inc. [15] (NASDAQ: CHRS) to receive FDA or EC approval.

"Vizient strongly believes that competition is essential to realizing meaningful price reductions on expensive oncology drugs and other biologics. According to an article recently published by the American Journal of Health-System Pharmacy, the annual U.S. expense on Neulasta exceeds $4 billion and we have seen prices for Neulasta escalate on the order of 10% per year," said Steven Lucio [16], associate vice president, pharmacy services, sourcing operations at Vizient. "We applaud FDA for expediting the approval of UDENYCA and the additional actions the Agency is taking to improve and expedite the introduction of biosimilar competition."

Vizient is the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers.

About Vizient, Inc.

Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2018, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com [14] as well as our newsroom [17], blog [18], Twitter [19], LinkedIn [20] and YouTube [21] pages for more information about the company.

Language:
English

Contact:

Vizient
Angie Boliver, 972-830-7961
angie.boliver@vizientinc.com [22]

Organization,Facebook,Vizient on Facebook [23]
Organization,LinkedIn,Vizient on LinkedIn [24]
Organization,Twitter,Vizient on Twitter [19]
Organization,YouTube,Vizient on YouTube [22]

@vizientinc

@Vizientinc applauds @US_FDA for approving UDENYCA, the second pegfilgrastim #biosimilar, for patients with #cancer receiving myelosuppressive chemotherapy. #hospitals


Links: